Clinical characteristics of the study patients
| Characteristic . | AL patients (n = 163) . |
|---|---|
| Age, y | 61.0 ± 0.7 |
| Male/female | 92 (56.4%)/71 (43.6%) |
| Body mass index, kg/m2 | 24.7 ± 0.3 |
| Lambda/kappa | 128 (56.4%)/35 (43.6%) |
| Amyloid organ involvement | 2.7 ± 0.1 |
| 1 organ involved | 23 (14.1%) |
| 2 organs involved | 55 (33.7%) |
| 3 or more organs involved | 85 (52.2%) |
| Dominant organ involvement | |
| Kidney | 79 (48.5%) |
| Heart | 64 (39.3%) |
| Liver | 15 (9.2%) |
| Peripheral nervous system | 5 (3.1%) |
| Soft tissues | 14 (8.6%) |
| Gastrointestinal | 7 (4.3%) |
| Clinical evidence of kidney involvement | |
| EGFR, mL × s−1 × 1.73 m−2 | 61.8 ± 2.7 |
| EGFR ≤ 60 mL × s−1 × 1.73 m−2 | 81 (49.7%) |
| EGFR ≤ 30 mL × s−1 × 1.73 m−2 | 39 (23.97%) |
| Dialysis at study inclusion | 27 (16.6%) |
| Clinical evidence of heart involvement | |
| Heart failure NYHA class | 1.7 ± 0.1 |
| NYHA I | 31 (19.0%) |
| NYHA II | 48 (29.5%) |
| NYHA III | 33 (20.2%) |
| NYHA IV | 1 (0.6%) |
| LA diameter, mm | 40.6 ± 0.5 |
| IVS thickness, mm | 15.5 ± 0.3 |
| Myocardial mass index, g × m−2 | 61.7 ± 1.5 |
| Fractional shortening, percentage | 33.2 ± 0.8 |
| Ejection fraction, < 45% | 30 (18.4%) |
| Granular sparkling | 72 (44.2%) |
| NT-proBNP, pg/mL | 7796 ± 1274 |
| Characteristic . | AL patients (n = 163) . |
|---|---|
| Age, y | 61.0 ± 0.7 |
| Male/female | 92 (56.4%)/71 (43.6%) |
| Body mass index, kg/m2 | 24.7 ± 0.3 |
| Lambda/kappa | 128 (56.4%)/35 (43.6%) |
| Amyloid organ involvement | 2.7 ± 0.1 |
| 1 organ involved | 23 (14.1%) |
| 2 organs involved | 55 (33.7%) |
| 3 or more organs involved | 85 (52.2%) |
| Dominant organ involvement | |
| Kidney | 79 (48.5%) |
| Heart | 64 (39.3%) |
| Liver | 15 (9.2%) |
| Peripheral nervous system | 5 (3.1%) |
| Soft tissues | 14 (8.6%) |
| Gastrointestinal | 7 (4.3%) |
| Clinical evidence of kidney involvement | |
| EGFR, mL × s−1 × 1.73 m−2 | 61.8 ± 2.7 |
| EGFR ≤ 60 mL × s−1 × 1.73 m−2 | 81 (49.7%) |
| EGFR ≤ 30 mL × s−1 × 1.73 m−2 | 39 (23.97%) |
| Dialysis at study inclusion | 27 (16.6%) |
| Clinical evidence of heart involvement | |
| Heart failure NYHA class | 1.7 ± 0.1 |
| NYHA I | 31 (19.0%) |
| NYHA II | 48 (29.5%) |
| NYHA III | 33 (20.2%) |
| NYHA IV | 1 (0.6%) |
| LA diameter, mm | 40.6 ± 0.5 |
| IVS thickness, mm | 15.5 ± 0.3 |
| Myocardial mass index, g × m−2 | 61.7 ± 1.5 |
| Fractional shortening, percentage | 33.2 ± 0.8 |
| Ejection fraction, < 45% | 30 (18.4%) |
| Granular sparkling | 72 (44.2%) |
| NT-proBNP, pg/mL | 7796 ± 1274 |
EGFR indicates estimated glomerular filtration rate; NYHA, New York Heart Association; and LA, left atrial.